HC Wainwright Issues Positive Estimate for Lipocine Earnings

Lipocine Inc. (NASDAQ:LPCN) – Research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of Lipocine in a note issued to investors on Monday, September 21st. HC Wainwright analyst Y. Chen now expects that the specialty pharmaceutical company will earn ($0.39) per share for the quarter, up from their prior estimate of ($0.47). HC Wainwright has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Lipocine’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Lipocine’s Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.54) EPS.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Lipocine in a research note on Tuesday. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Lipocine presently has an average rating of “Hold” and an average target price of $4.00.

Lipocine Price Performance

Shares of LPCN opened at $2.16 on Wednesday. The stock’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $3.03. Lipocine has a 1 year low of $1.81 and a 1 year high of $12.37. The firm has a market cap of $17.80 million, a PE ratio of -1.21 and a beta of 0.47.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.08. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%.

Institutional Trading of Lipocine

A number of institutional investors have recently modified their holdings of LPCN. Eversept Partners LP bought a new position in shares of Lipocine during the first quarter valued at approximately $2,357,000. AIGH Capital Management LLC purchased a new stake in shares of Lipocine in the 1st quarter worth about $1,598,000. Stempoint Capital LP bought a new stake in Lipocine during the first quarter worth about $1,282,000. Seven Fleet Capital Management LP purchased a new stake in Lipocine in the first quarter worth about $998,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Lipocine during the fourth quarter valued at approximately $567,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.